M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1279-1286

  Prokop, Stefan ^a   Heppner, Frank L ^a   Goebel, Hans H ^a,b   Stenzel, Werner ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME SYNTHESIS; FEMALE; GIANT CELL; HUMAN; HUMAN TISSUE; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MONOCYTE; MYOFIBROSIS; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOIDOSIS; TH2 CELL; UPREGULATION;

EID: 79952754822     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.065     Document Type: Article

References (52)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416
2. + T cells in sarcoidosis. Proc Am Thorac Soc 2007, 4:461-464
3. Morey SS: American Thoracic Society issues consensus statement on sarcoidosis. Am Fam Physician 2000, 61:553-554, 556
4. Parrish S, Turner JF: Diagnosis of sarcoidosis. Dis Mon 2009, 55:693-703
5. Lazarus A: Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 2009, 55:649-660
6. Chen ES, Moller DR: Etiology of sarcoidosis. Clin Chest Med 2008, 29:365-377, vii
7. Agostini C, Adami F, Semenzato G: New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 2000, 12:71-76 (Pubitemid 30036691)
8. Semenzato G, Adami F, Maschio N, Agostini C: Immune mechanisms in interstitial lung diseases. Allergy 2000, 55:1103-1120
9. Ziegenhagen MW, Muller-Quernheim J: The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003, 253:18-30 (Pubitemid 36120994)
10. Moller DR: Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc 2007, 4:465-468
11. Hiramatsu J, Kataoka M, Nakata Y, Okazaki K, Tada S, Tanimoto M, Eishi Y: Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20:197-203 (Pubitemid 37351541)
12. Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 2007, 357:2153-2165
13. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H, Jr, Johns CJ, Rabin DL, Rybicki BA, Cherniack R: A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004, 170:1324-1330 (Pubitemid 39657197)
14. Faurie P, Broussolle C, Zoulim F, Trepo C, Seve P: Sarcoidosis and hepatitis C: clinical description of 11 cases. Eur J Gastroenterol Hepatol 2010, 22:967-972
15. Doyle MK, Berggren R, Magnus JH: Interferon-induced sarcoidosis. J Clin Rheumatol 2006, 12:241-248 (Pubitemid 44527044)
16. Dasilva V, Breuil V, Chevallier P, Euller-Ziegler L: Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFα blockade: efficacy of rituximab, report of a single case. Joint Bone Spine 2010, 77:82-83
17. Stjernberg N, Cajander S, Truedsson H, Uddenfeldt P: Muscle involvement in sarcoidosis. Acta Med Scand 1981, 209:213-216 (Pubitemid 11114045)
18. Zissel G, Prasse A, Muller-Quernheim J: Sarcoidosis: immunopathogenetic concepts. Semin Respir Crit Care Med 2007, 28:3-14
19. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184 (Pubitemid 46048464)
20. Martinez FO, Helming L, Gordon S: Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483
21. Mosser DM: The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212
22. Mylonas KJ, Nair MG, Prieto-Lafuente L, Paape D, Allen JE: Alternatively activated macrophages elicited by helminth infection can be reprogrammed to enable microbial killing. J Immunol 2009, 182:3084-3094
23. Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G: M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol 2009, 182:6237-6246
24. Stenzel W, Dahm J, Sanchez-Ruiz M, Miletic H, Hermann M, Courts C, Schwindt H, Utermohlen O, Schluter D, Deckert M: Regulation of the inflammatory response to Staphylococcus aureus-induced brain abscess by interleukin-10. J Neuropathol Exp Neurol 2005, 64:1046-1057
25. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408 (Pubitemid 34164012)
26. Ruckerl D, Hessmann M, Yoshimoto T, Ehlers S, Holscher C: Alternatively activated macrophages express the IL-27 receptor α chain WSX-1. Immunobiology 2006, 211:427-436
27. Helming L, Tomasello E, Kyriakides TR, Martinez FO, Takai T, Gordon S, Vivier E: Essential role of DAP12 signaling in macrophage programming into a fusion-competent state. Sci Signal 2008, 1:ra11
28. Kinjo Y, Kawakami K, Uezu K, Yara S, Miyagi K, Koguchi Y, Hoshino T, Okamoto M, Kawase Y, Yokota K, Yoshino K, Takeda K, Akira S, Saito A: Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. J Immunol 2002, 169:323-329 (Pubitemid 34686152)
29. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G: A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173:781-792
30. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, Holden DA, Forrester JM, Lazarus A, Wysocka M, Trinchieri G, Karp C: Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996, 156:4952-4960 (Pubitemid 26174485)
31. Robinson BW, McLemore TL, Crystal RG: Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985, 75:1488-1495 (Pubitemid 15041440)
32. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16:149-173
33. Baumer I, Zissel G, Schlaak M, Muller-Quernheim J: Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997, 16:171-177 (Pubitemid 127498238)
34. Parronchi P, Mohapatra S, Sampognaro S, Giannarini L, Wahn U, Chong P, Mohapatra S, Maggi E, Renz H, Romagnani S: Effects of interferon-α on cytokine profile: T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996, 26:697-703 (Pubitemid 26091402)
35. Hurst EA, Mauro T: Sarcoidosis associated with pegylated interferon α and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005, 141:865-868 (Pubitemid 41058068)
36. Benali S, Boustiere C, Castellani P, Cesari C, Jullien M, Lecomte L, Lebars O, Lambot G, Loyer R, Masseboeuf A, Perrier H, Oules V, Bourliere M: [Sarcoidosis following pegylated interferon therapy: two cases]. French. Gastroenterol Clin Biol 2006, 30:615-619
37. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, Cervera R, Font J: Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 2005, 84:69-80 (Pubitemid 40418635)
38. Goldberg HJ, Fiedler D, Webb A, Jagirdar J, Hoyumpa AM, Peters J: Sarcoidosis after treatment with interferon-α: a case series and review of the literature. Respir Med 2006, 100:2063-2068
39. Möllers M, Aries SP, Dromann D, Mascher B, Braun J, Dalhoff K: Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax 2001, 56:487-493 (Pubitemid 32521369)
40. Hauber HP, Gholami D, Meyer A, Pforte A: Increased interleukin-13 expression in patients with sarcoidosis. Thorax 2003, 58:519-524 (Pubitemid 36714015)
41. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779-788 (Pubitemid 29152623)
42. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964 (Pubitemid 41746764)
43. Varin A, Gordon S: Alternative activation of macrophages: immune function and cellular biology. Immunobiology 2009, 214:630-641
44. Desguerre I, Mayer M, Leturcq F, Barbet JP, Gherardi RK, Christov C: Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 2009, 68:762-773
45. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, Guillot P, Hakiy N, Klemke CD, Dippel E, Kodelja V, Orfanos CE: Alternative versus classical activation of macrophages. Pathobiology 1999, 67:222-226 (Pubitemid 30135909)
46. Kodelja V, Muller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S: Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 1997, 197:478-493 (Pubitemid 27489996)
47. Liu Y, Stewart KN, Bishop E, Marek CJ, Kluth DC, Rees AJ, Wilson HM: Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol 2008, 180:6270-6278
48. Helming L, Gordon S: The molecular basis of macrophage fusion. Immunobiology 2007, 212:785-793 (Pubitemid 350246267)
49. Helming L, Gordon S: Molecular mediators of macrophage fusion. Trends Cell Biol 2009, 19:514-522
50. Helming L, Gordon S: Macrophage fusion induced by IL-4 alternative activation is a multistage process involving multiple target molecules. Eur J Immunol 2007, 37:33-42 (Pubitemid 46128784)
51. Chensue SW, Terebuh PD, Warmington KS, Hershey SD, Evanoff HL, Kunkel SL, Higashi GI: Role of IL-4 and IFN-γ in Schistosoma mansoni egg-induced hypersensitivity granuloma formation: orchestration, relative contribution, and relationship to macrophage function. J Immunol 1992, 148:900-906
52. Kao WJ, McNally AK, Hiltner A, Anderson JM: Role for interleukin-4 in foreign-body giant cell formation on a poly(etherurethane urea) in vivo. J Biomed Mater Res 1995, 29:1267-1275